Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women

Clinical Infectious Diseases

Volumn 44, Issue 12, 2007, Pages 1647-1656

  Patel, Deven ^a   Cortina Borja, Mario ^a   Thorne, Claire ^a   Newell, Marie Louise ^a   Giaquinto, C ^b   Rampon, O ^b   D'Elia, R ^b   De Rossi, A ^b   Grosch Worner I ^c   Mok, J ^d   De Jose I ^e   Laaru ^e   Bates, I ^e   Salas, A ^e   Ma Pena J ^e   Gonzalez Garcia, J ^e   Arribas Lopez, J R ^e   Garcia Rodriguez, M C ^e   Asensi Botet, F ^f   Otero, M C ^f   Perez Tamarit D ^f   Scherpbier, H J ^g   Kreyenbroek, M ^g   Godfried, M H ^g   Nellen, F J B ^g   Boer, K ^g   Bohlin, A B ^h   Lindgren, S ^h   Anzen B ^h   Lidman, K ^h   Elfgren, K ^h   Gyllensten, K ^h   Pehrson, P O ^h   Levy, J ⁱ   Barlow, P ⁱ   Manigart, Y ⁱ   Hainaut, M ⁱ   Peltier, A ⁱ   Goetghebuer, T ⁱ   Ferrazin, A ^j   De Maria, A ^k   Bentivoglio, G ^j   Ferrero, S ^j   Gotta, C ^j   Mur A ^l   Paya A ^l   Lopez Vilchez M A ^l   Carreras, R ^l   Valerius, N H ^m   Rosenfeldt, V ^m   Jimenez, J ⁿ   Coll, O ^o   Suy, A ^o   Perez, J M ^o   Fortuny, C ^p   Boguna J ^p   Casellas Caro, M ^q   Canet, Y ^r   Pardi, G ^s   Ravizza, M ^s   Guerra, B ^t   Lanari, M ^t   Bianchi, S ^t   Bovicelli, L ^t   Prati, E ^u   Duse, M ^u   Scaravelli, G ^v   Stegagno, M ^v   De Santis, M ^w   Savasi, V ^x   Fiore, S ^x   Crivelli, M ^x   Ferrazzi, E ^x   Vigano A ^x   Giacomet, V ^x   Frasca, D ^x   Zuccotti, G ^x   Ravagni Probizer, F ^y   Maccabruni, A ^y   Bucceri, A ^z   Rancilio, L ^z   Alberico, S ^aa   Rabusin, M ^aa   Bernardon, M ^aa   Taylor, G P ^ab   Lyall, E G H ^ab   Penn, Z ^ac   Buffolano, W ^ad   Tiseo, R ^ad   Martinelli, P ^ad   Sansone, M ^ad   Maruotti, G ^ad   Agangi, A ^ad   Tibaldi, C ^ae   Marini, S ^ae   Masuelli, G ^ae   Benedetto, C ^ae   Niemiec T ^af   Marczynska, M ^ag   Dobosz, S ^ag   Popielska, J ^ag   Oldakowska, A ^ag   Malyuta, R ^ah   Semenenko, I ^ah   Pilipenko, T ^ah   Posokhova, S ^ai   Kaleeva, T ^ai   Stelmah, A ^ai   Kiseleva, G ^ai   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PADOVA   (Italy)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^e HOSPITAL INFANTIL LA PAZ   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^j UNIVERSITY OF GENOA   (Italy)

^k UNIVERSITY OF GENOA   (Italy)

^l UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^m HVIDOVRE HOSPITAL   (Denmark)

ⁿ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^o HOSPITAL CLÍNIC   (Spain)

^p HOSPITAL SANT JOAN DE DÉU   (Spain)

^q HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^r HOSPITAL DE SABADELL   (Spain)

^s Azienda Ospedaliera San Paolo   (Italy)

^t UNIVERSITY OF BOLOGNA   (Italy)

^u UNIVERSITY OF BRESCIA   (Italy)

^v SAPIENZA UNIVERSITY OF ROME   (Italy)

^w CATHOLIC UNIVERSITY   (Italy)

^x UNIVERSITY OF MILAN   (Italy)

^y FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^z Clinica Pediatrica De Marchi   (Italy)

^aa INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^ab ST MARY S HOSPITAL   (United Kingdom)

^ac CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^ad UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^ae UNIVERSITY OF TURIN   (Italy)

^af INSTITUTE OF MOTHER AND CHILD   (Poland)

^ag MEDICAL UNIVERSITY OF WARSAW   (Poland)

^ah ECS Ukraine Coordinating Centre   (Ukraine)

^ai NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ARTICLE; DELIVERY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; RACE DIFFERENCE; SURVIVAL; TREATMENT OUTCOME; VIRUS LOAD;

EID: 34249874358     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/518284     Document Type: Article

References (37)

1. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999; 341:385-93.
2. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40:458-65.
3. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29:484-94.
4. European Collaborative Study. The mother-to-child HIV transmission epidemic in Europe: evolving in the Last and established in the West. AIDS 2006; 20:1419-27.
5. Lindsey JC, Ryan LM. Tutorial in biostatistics methods for interval-censored data. Stat Med 1998; 17:219-38.
6. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17:2265-81.
7. Giolo SR. Turnbull's nonparametric estimator for interval-censored data. Technical report 2004. Available at: http://www.est.ufpr.br/rt/ suely04a.pdf. Accessed 9 October 2006.
8. Public Health Service Taskforce. Safety and toxicity of individual antiretroviral agents in pregnancy. Available at: http://aidsinfo.nih.gov/. Accessed 9 October 2006.
9. British HIV Association. Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission of HIV. http://www.bhiva.org/guidelines/2005/pregnancy/. Accessed 9 October 2006.
10. Public Health Service Taskforce. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Available at: http://aidsinfo.nih.gov/. Accessed 9 October 2006.
11. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/. Accessed 9 October 2006.
12. Mocroft A, Phillips AN, Ledergerber 15, et al. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS 2006; 20:1141-50.
13. Chou R, Fu R, Huffman LH, Korthuis PT. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses. Lancet 2006; 368:1503-15.
14. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004; 43:1071-87.
15. Villani P, Floridia M, Pirillo MF, et al. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br J Clin Pharmacol 2006; 62:309-15.
16. Nellen JF, Schillevoort I, Wit FW, et al. Nelfinavir plasma concentrations are low during pregnancy. Clin Infect Dis 2004; 39:736-40.
17. van Heeswijk RP, Khaliq Y, Gallicano KD, et al. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharmacol Ther 2004; 76:588-97.
18. Podzamczer D, Ferrer E, Consiglio E, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther 2002; 7:81-90.
19. Taha TE, Brown ER, Hoffman IF, et al. A phase III clinical trial of antibiotics to reduce chorioamnionitis-related perinatal HIV-1 transmission. AIDS 2006; 20:1313-21.
20. Shapiro RL, Thior I, Gilbert PB, et al. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS 2006; 20:1281-8.
21. Giuliano M, Guidotti G, Andreotti M, et al. Triple antiretroviral therapy administered during pregnancy and after delivery significantly reduces breast milk viral load [abstract 727]. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (Denver). 2006.
22. Frater AJ, Dunn DT, Beardall AJ, et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 2002; 16:1139-46.
23. Cunningham CK, Balasubramanian R, Delke I, et al. The impact of race/ethnicity on mother-to-child HIV transmission in the United States in Pediatric AIDS Clinical Trials Group Protocol 316. J Acquir Immune Defic Syndr 2004; 36:800-7.
24. Anastos K, Gauge SJ, Lau B, et al. Association of race and gender with HIV-1 RNA levels and immunologic progression. J Acquir Immune Defic Syndr 2000; 24:218-26.
25. Bocket L, Cheret A, Deuffic-Burban S, et al. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antivir Ther 2005; 10:247-54.
26. Geretti AM. HIV-1 subtypes: epidemiology and significance for HIV management. Curr Opin Infect Dis 2006; 19:1-7.
27. Brumme ZL, Harrigan PR. The impact of human genetic variation on HIV disease in the era of HAART. AIDS Rev 2006; 8:78-87.
28. Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001; 286:2560-7.
29. Matthews GV, Sabin CA, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS 2002; 16:53-61.
30. Melvin AJ, Burchett SK, Watts DH, et al. Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women. J Acquir Immune Defic Syndr Hum Retroviral 1997; 14:232-6.
31. Burns DN, Landesman S, Minkoff H, et al. The influence of pregnancy on human immunodeficiency virus type 1 infection: antepartum and postpartum changes in human immunodeficiency virus type 1 viral load. Am J Obstet Gynecol 1998; 178:355-9.
32. Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS 1999; 13:2075-82.
33. Stebbing J, Bower M. Comparative pharmacogenomics of antiretroviral and cytotoxic treatments. Lancet Oncol 2006; 7:61-8.
34. Lowe SH, Prins JM, Lange JM. Antiretroviral therapy in previously untreated adults infected with the human immunodeficiency virus type 1: established and potential determinants of virological outcome. Neth J Med 2004; 62:424-40.
35. World Health Organization. Anitretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Geneva, Switzerland: World Health Organization, 2006.
36. Bartlett JA, Fath MJ, Demasi R, et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006; 20:2051-64.
37. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS 2006; 20:1931-9.